369 related articles for article (PubMed ID: 11743279)
1. Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: a decision analytical approach.
Lotan Y; Roehrborn CG
J Urol; 2002 Jan; 167(1):75-9. PubMed ID: 11743279
[TBL] [Abstract][Full Text] [Related]
2. Economic impact of tumor markers in bladder cancer surveillance.
Hong YM; Loughlin KR
Urology; 2008 Jan; 71(1):131-5. PubMed ID: 18242381
[TBL] [Abstract][Full Text] [Related]
3. Should we screen for bladder cancer in a high-risk population?: A cost per life-year saved analysis.
Lotan Y; Svatek RS; Sagalowsky AI
Cancer; 2006 Sep; 107(5):982-90. PubMed ID: 16862567
[TBL] [Abstract][Full Text] [Related]
4. Comparison of molecular and conventional strategies for followup of superficial bladder cancer using decision analysis.
Nam RK; Redelmeier DA; Spiess PE; Sampson HA; Fradet Y; Jewett MA
J Urol; 2000 Mar; 163(3):752-7. PubMed ID: 10687970
[TBL] [Abstract][Full Text] [Related]
5. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
6. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study.
Pfister C; Chautard D; Devonec M; Perrin P; Chopin D; Rischmann P; Bouchot O; Beurton D; Coulange C; Rambeaud JJ
J Urol; 2003 Mar; 169(3):921-4. PubMed ID: 12576813
[TBL] [Abstract][Full Text] [Related]
7. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
Kumar A; Kumar R; Gupta NP
Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
[TBL] [Abstract][Full Text] [Related]
8. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
[TBL] [Abstract][Full Text] [Related]
9. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
10. Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors.
Filbeck T; Pichlmeier U; Knuechel R; Wieland WF; Roessler W
J Urol; 2002 Jul; 168(1):67-71. PubMed ID: 12050494
[TBL] [Abstract][Full Text] [Related]
11. Early diagnosis and monitoring of superficial transitional cell carcinoma by microsatellite analysis on urine sediment.
Bartoletti R; Dal Canto M; Cai T; Piazzini M; Travaglini F; Gavazzi A; Rizzo M
Oncol Rep; 2005 Mar; 13(3):531-7. PubMed ID: 15706429
[TBL] [Abstract][Full Text] [Related]
12. [Molecular markers for transitional cell carcinoma of bladder].
Kleinmann J; Siegel YI; Zisman A
Harefuah; 2003 Jul; 142(7):531-5, 565. PubMed ID: 12908389
[TBL] [Abstract][Full Text] [Related]
13. Non-muscle-invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost-effective alternative?
de Bekker-Grob EW; van der Aa MN; Zwarthoff EC; Eijkemans MJ; van Rhijn BW; van der Kwast TH; Steyerberg EW
BJU Int; 2009 Jul; 104(1):41-7. PubMed ID: 19500328
[TBL] [Abstract][Full Text] [Related]
14. Urine cytology in the follow-up of patients with transitional cell carcinoma of the urinary bladder: is that enough as a single method?
Raica M; Miclea F; Ioiart I; Minciu R; Drăgan P
Rom J Morphol Embryol; 1998; 44(1-4):173-8. PubMed ID: 15678859
[TBL] [Abstract][Full Text] [Related]
15. uCyt+ test: alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma.
Lodde M; Mian C; Comploj E; Palermo S; Longhi E; Marberger M; Pycha A
Urology; 2006 May; 67(5):950-4. PubMed ID: 16698355
[TBL] [Abstract][Full Text] [Related]
16. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
[TBL] [Abstract][Full Text] [Related]
17. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology.
Skacel M; Fahmy M; Brainard JA; Pettay JD; Biscotti CV; Liou LS; Procop GW; Jones JS; Ulchaker J; Zippe CD; Tubbs RR
J Urol; 2003 Jun; 169(6):2101-5. PubMed ID: 12771727
[TBL] [Abstract][Full Text] [Related]
18. A prospective evaluation of the diagnostic and potential prognostic utility of urinary human telomerase reverse transcriptase mRNA in patients with bladder cancer.
Bowles L; Bialkowska-Hobrzanska H; Bukala B; Nott L; Razvi H
Can J Urol; 2004 Dec; 11(6):2438-44. PubMed ID: 15636669
[TBL] [Abstract][Full Text] [Related]
19. Accuracy of the ImmunoCyt assay in the diagnosis of transitional cell carcinoma of the urinary bladder.
Feil G; Zumbrägel A; Päulgen-Nelde HJ; Hennenlotter J; Maurer S; Krause S; Bichler KH; Stenzl A
Anticancer Res; 2003; 23(2A):963-7. PubMed ID: 12820331
[TBL] [Abstract][Full Text] [Related]
20. Management of low grade papillary bladder tumors.
Herr HW; Donat SM; Reuter VE
J Urol; 2007 Oct; 178(4 Pt 1):1201-5; discussion 1205. PubMed ID: 17698090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]